Lexeo Therapeutics (LXEO) Other financing activities (2022 - 2026)
Lexeo Therapeutics (LXEO) posted Other financing activities of $9000.0 for Q1 2026, down 64.0% sequentially from $25000.0 in Q4 2025.
Lexeo Therapeutics (LXEO) Other financing activities (2022 - 2026) Analysis & Trends
Lexeo Therapeutics has reported Other financing activities for 5 years, with the latest figure at $9000.0 in Q1 2026.
- Quarterly Other financing activities changed N/A year-over-year to $9000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$94.5 million (changed N/A YoY) and the FY2025 annual result came in at $59000.0, down 87.98% from the prior year.
- Other financing activities slipped to $9000.0 in Q1 2026 per LXEO's latest filing, from $25000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $88.8 million in Q1 2024 and troughed at -$94.5 million in Q4 2024.
- A 5-year average of $67111.1 and a median of $25000.0 in 2025 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2024 and 2025: Other financing activities surged 739508.33% in 2024, then surged 100.03% in 2025.
- Over 5 years, Other financing activities stood at $28000.0 in 2022, then increased by 7.14% to $30000.0 in 2023, then tumbled by 315126.67% to -$94.5 million in 2024, then soared by 100.03% to $25000.0 in 2025, then sank by 64.0% to $9000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $9000.0, $25000.0, and -$94.5 million for Q1 2026, Q4 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lexeo Therapeutics | 397.10 Mn | 397.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9,000.00 |
| Mar 31, 2026 | 9,000.00 |
| Dec 31, 2025 | 25,000.00 |
| Dec 31, 2025 | 25,000.00 |
| Dec 31, 2024 | -94.51 Mn |
| Dec 31, 2024 | -94.51 Mn |
| Jun 30, 2024 | 6.25 Mn |
| Jun 30, 2024 | 6.25 Mn |
| Mar 31, 2024 | 88.75 Mn |
| Mar 31, 2024 | 88.75 Mn |
| Sep 30, 2023 | 30,000.00 |
| Sep 30, 2023 | 30,000.00 |
| Jun 30, 2023 | 9,000.00 |
| Jun 30, 2023 | 9,000.00 |
| Mar 31, 2023 | 12,000.00 |
| Mar 31, 2023 | 12,000.00 |
| Dec 31, 2022 | 28,000.00 |
| Dec 31, 2022 | 28,000.00 |